

## **Diabetes Workgroup, August 2006**

Following review and discussion, the workgroup recommends to the Pharmacy and Therapeutics Committee the following:

### **Amylin Analogs:**

No change

### **Secretin Mimetics:**

No change

### **Insulins:**

Subdivide this large class into five: Basal Insulins; Rapid Acting Insulins; Insulin Mixes; Traditional Insulins; Inhaled Insulins

For “Basal Insulins”, add Levemir® and Lantus® without prior authorization(PA)

For “Rapid Acting Insulins”, add Apidra®, Humalog®, Novalog® without PA

For “Insulin Mixes”, add Humalog 50/50, 75/25, Humulin 50/50, Novolin 70/30, Novolog 70/30 without PA; add Humulin 70/30 with PA

For “Traditional Insulins”, add Humulin L, R 500U, U, Novolin L, N, R, Velosulin BR without PA; add Humulin N, R with PA; continue Iletin I Lente, N, R, Iletin II Pork L, Pork N, Pork R with PA

For “Inhaled Insulins”, add Exubera® with PA; develop a fax form that requests the information desired for approval criteria for Exubera®; review utilization at six months and bring results back to the full committee

### **Oral Hypoglycemics-Alpha Glucosidase Inh**

No change

### **Oral Hypoglycemics-Biguanides**

No change

### **Oral Hypoglycemics-Biguanide Combinations**

Change name to “Oral Hypoglycemics-Combinations”

No change to current status of drugs listed

### **Oral Hypoglycemics- Meglitinides**

No change

### **Oral Hypoglycemics-2<sup>nd</sup> Generation Sulfonylureas**

Add Glimiperide to list of drugs available without PA

No changes to current listing of drug products

### **Oral Hypoglycemics-Thiazolidineiones**

Remove PA from Avandia®